See more : Lang & Schwarz Aktiengesellschaft (LUS.DE) Income Statement Analysis – Financial Results
Complete financial analysis of eFFECTOR Therapeutics, Inc. (EFTR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of eFFECTOR Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- STIF Société anonyme (ALSTI.PA) Income Statement Analysis – Financial Results
- Solar Industries India Limited (SOLARINDS.BO) Income Statement Analysis – Financial Results
- Kismet Acquisition Three Corp. (KIIIU) Income Statement Analysis – Financial Results
- China Coal Energy Company Limited (1898.HK) Income Statement Analysis – Financial Results
- Telefonaktiebolaget LM Ericsson (publ) (ERIC-A.ST) Income Statement Analysis – Financial Results
eFFECTOR Therapeutics, Inc. (EFTR)
About eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 3.55M | 1.43M | 42.00M | 0.00 |
| Cost of Revenue | 22.92M | 53.00K | 24.00K | 21.83M | 307.00K |
| Gross Profit | -22.92M | 3.50M | 1.41M | 20.17M | -307.00K |
| Gross Profit Ratio | 0.00% | 98.51% | 98.32% | 48.02% | 0.00% |
| Research & Development | 22.92M | 23.31M | 19.96M | 21.83M | 23.58M |
| General & Administrative | 10.93M | 12.64M | 13.37M | 4.35M | 4.72M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.93M | 12.64M | 13.37M | 4.35M | 4.72M |
| Other Expenses | 0.00 | -3.55M | -1.43M | 9.00K | 0.00 |
| Operating Expenses | 33.84M | 32.40M | 31.90M | 26.18M | 28.30M |
| Cost & Expenses | 33.84M | 32.40M | 31.90M | 26.18M | 28.61M |
| Interest Income | 1.95M | 439.00K | 6.00K | 67.00K | 239.00K |
| Interest Expense | 0.00 | 2.25M | 1.76M | 1.33M | 1.38M |
| Depreciation & Amortization | 111.00K | 53.00K | 24.00K | 160.00K | 307.00K |
| EBITDA | -33.73M | -32.40M | -31.90M | 16.06M | -28.30M |
| EBITDA Ratio | 0.00% | -911.99% | -2,230.56% | 38.23% | 0.00% |
| Operating Income | -33.84M | -32.40M | -31.90M | 15.82M | -28.61M |
| Operating Income Ratio | 0.00% | -911.99% | -2,230.56% | 37.66% | 0.00% |
| Total Other Income/Expenses | -1.97M | 9.74M | 47.70M | -1.26M | -1.13M |
| Income Before Tax | -35.81M | -22.67M | 15.80M | 14.56M | -29.74M |
| Income Before Tax Ratio | 0.00% | -637.91% | 1,104.76% | 34.67% | 0.00% |
| Income Tax Expense | 0.00 | -9.74M | -24.00K | 351.00K | 135.14K |
| Net Income | -35.81M | -12.93M | 15.80M | 14.21M | -29.74M |
| Net Income Ratio | 0.00% | -363.83% | 1,104.76% | 33.84% | 0.00% |
| EPS | -16.37 | -7.85 | 9.78 | 23.74 | -53.83 |
| EPS Diluted | -16.37 | -7.85 | 9.78 | 23.74 | -53.83 |
| Weighted Avg Shares Out | 2.19M | 1.65M | 1.62M | 598.56K | 552.43K |
| Weighted Avg Shares Out (Dil) | 2.19M | 1.65M | 1.62M | 598.56K | 552.43K |
BioGene Therapeutics Announces Appointment of Dr. Brian Gallagher, Jr. to Corporate Advisory Board
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is...
3 Publicly Traded Companies Filing for Bankruptcy as July Kicks Off
As the stock market hits new highs in July, investors are riding a wave of optimism, closely tracking climbing indexes. Yet, beneath this bullish surface, some publicly traded companies are becoming bankruptcy risk stocks as they're grappling with the stark...
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) today announced that the Company has terminated its employees and will wind down it operations, including seeking potential strategic alternatives for the...
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a collaboration to conduct...
EFTR Stock Earnings: eFFECTOR Therapeutics Meets EPS for Q1 2024
eFFECTOR Therapeutics (NASDAQ: EFTR ) just reported results for the first quarter of 2024. eFFECTOR Therapeutics reported earnings per share of -$2.16.
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024 Raised $15.0 million in gross proceeds from registered direct financing, extending cash runway into first quarter of 2025 SOLANA BEACH, Calif. and...
eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the Company will...
eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails
eFFECTOR Therapeutics (EFTR) plunges on disappointing top-line results from the primary analysis of its mid-stage NSCLC study of tomivosertib, following the abandonment of the developmental program.
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced topline results from the...
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expected in early April 2024
Source: https://incomestatements.info
Category: Stock Reports